Pages that link to "Q34157899"

The following pages link to Developments in clinical cell therapy (Q34157899):

Displaying 17 items.

• Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study (Q33427019) (← links)
• Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients (Q34450648) (← links)
• Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors (Q34635795) (← links)
• Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy (Q34918975) (← links)
• Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer (Q36422925) (← links)
• Near-infrared lipophilic fluorophores for tracing tissue growth (Q36660726) (← links)
• Highly charged cyanine fluorophores for trafficking scaffold degradation (Q36693383) (← links)
• An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy (Q37735515) (← links)
• MicroRNA profiling of CD3 CD56 cytokine-induced killer cells (Q37737350) (← links)
• Review of Chinese clinical trials on CIK cell treatment for malignancies (Q37981003) (← links)
• Efficacy of adoptive cellular therapy in patients with gastric cancer: a meta-analysis (Q38887317) (← links)
• Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study (Q45246341) (← links)
• The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma (Q45354258) (← links)
• All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion (Q47111085) (← links)
• Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment (Q47115641) (← links)
• Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients (Q47354391) (← links)
• Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer (Q89931341) (← links)